Vectura Group (LON:VEC)‘s stock had its “buy” rating reissued by Peel Hunt in a report issued on Tuesday, ThisIsMoney.Co.Uk reports.

A number of other research analysts have also commented on the company. Shore Capital reiterated a “hold” rating on shares of Vectura Group in a research report on Wednesday, November 27th. JPMorgan Chase & Co. increased their price objective on Vectura Group from GBX 110 ($1.45) to GBX 120 ($1.58) and gave the company an “overweight” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Vectura Group has a consensus rating of “Buy” and an average price target of GBX 138.50 ($1.82).

VEC traded up GBX 5.30 ($0.07) during mid-day trading on Tuesday, reaching GBX 67.30 ($0.89). The stock had a trading volume of 2,261,018 shares, compared to its average volume of 4,610,000. The stock has a market capitalization of $408.34 million and a P/E ratio of -5.26. The company has a debt-to-equity ratio of 1.73, a quick ratio of 2.41 and a current ratio of 2.84. The firm’s fifty day simple moving average is GBX 88.86 and its two-hundred day simple moving average is GBX 87.33. Vectura Group has a 52 week low of GBX 65.90 ($0.87) and a 52 week high of GBX 102.24 ($1.34).

About Vectura Group

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

Further Reading: Outstanding Shares

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with's FREE daily email newsletter.